Form 8-K - Current report:
SEC Accession No. 0001193125-24-001884
Filing Date
2024-01-04
Accepted
2024-01-04 07:08:52
Documents
14
Period of Report
2024-01-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d378650d8k.htm   iXBRL 8-K 36688
2 EX-99.1 d378650dex991.htm EX-99.1 20646
6 GRAPHIC g378650gdsp1.jpg GRAPHIC 5044
  Complete submission text file 0001193125-24-001884.txt   197424

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20240104.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20240104_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20240104_pre.xml EX-101.PRE 11262
8 EXTRACTED XBRL INSTANCE DOCUMENT d378650d8k_htm.xml XML 3360
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 24509745
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)